Log In
Print
BCIQ
Print
Print this Print this
 

JX-929

  Manage Alerts
Collapse Summary General Information
Company SillaJen Inc.
DescriptionRecombinant vaccinia virus
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionOncolytic virus
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat superficial injectable tumors
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today